AD · Neurology · 4 drugs · 3 indications
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|---|---|---|---|---|
| Trontinemab | ROG.SW | — | Bispecific | IV | PHASE2 |
| Bepranemab | UCB | Tau clearance | Antibody | IV | PHASE2 |
| Kisunla | LLY | Amyloid-beta clearance | Antibody | IV | APPROVED |
| Rexulti | 4578 | Serotonin-Dopamine Activity Modulator (SDAM) | Small molecule | ORAL | APPROVED |